Premium
The effects of acute and repeated doses of moclobemide on psychomotor performance and cognitive function in healthy elderly volunteers
Author(s) -
Kerr J. S.,
Fairweather D. B.,
Hindmarch I.
Publication year - 1992
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470070407
Subject(s) - moclobemide , flicker fusion threshold , psychomotor learning , amitriptyline , psychology , placebo , anesthesia , cognition , psychomotor agitation , sedation , audiology , effects of sleep deprivation on cognitive performance , medicine , cognitive test , psychiatry , antidepressant , flicker , anxiety , alternative medicine , pathology , electrical engineering , engineering
The effects of moclobemide, a new selective and reversible MAO‐A inhibitor, on cognitive function and psychomotor performance were measured in 12 healthy elderly male volunteers (with a mean age of 72.5 years). Subjects received moclobemide 200 mg, amitriptyline (positive internal control) 25 mg or placebo twice daily and were assessed on a battery of psychometric tests on the mornings following the first (acute) day and seventh (sub‐chronic) day. The tests were: Choice Reaction Time; Tracking; Critical Flicker Fusion Threshold; Memory Scanning; Continuous Attention Task; the Leeds Sleep Evaluation Questionnaire and a Visual Line Analogue Rating Scale. The results show that amitriptyline produced impairment of cognitive and psychomotor functions. Moclobemide, however, did not disrupt sleep or cause daytime sedation, and remained neutral in the assessment of behavioural toxicity.